Leprosy disease remains an important public health issue as it is still endemic in several countries. , the causative agent of leprosy, presents tropism for cells of the reticuloendothelial and peripheral nervous system. Current multidrug therapy consists of clofazimine, dapsone and rifampicin. Despite significant improvements in leprosy treatment, in most programs, successful completion of the therapy is still sub-optimal. Drug resistance has emerged in some countries. This review discusses the status of leprosy disease worldwide, providing information regarding infectious agents, clinical manifestations, diagnosis, actual treatment and future perspectives and strategies on targets for an efficient targeted delivery therapy.
BT - Pharmaceutics C1 - https://www.ncbi.nlm.nih.gov/pubmed/33322356 DA - 12/2020 DO - 10.3390/pharmaceutics12121202 IS - 12 J2 - Pharmaceutics LA - eng N2 -Leprosy disease remains an important public health issue as it is still endemic in several countries. , the causative agent of leprosy, presents tropism for cells of the reticuloendothelial and peripheral nervous system. Current multidrug therapy consists of clofazimine, dapsone and rifampicin. Despite significant improvements in leprosy treatment, in most programs, successful completion of the therapy is still sub-optimal. Drug resistance has emerged in some countries. This review discusses the status of leprosy disease worldwide, providing information regarding infectious agents, clinical manifestations, diagnosis, actual treatment and future perspectives and strategies on targets for an efficient targeted delivery therapy.
PY - 2020 T2 - Pharmaceutics TI - Drug Delivery Systems on Leprosy Therapy: Moving Towards Eradication? UR - https://www.mdpi.com/1999-4923/12/12/1202/htm VL - 12 SN - 1999-4923 ER -